Optimization of transplantation of cell suspension in the treatment of vitiligo

Optimization of autologous melanocyte and keratinocyte cells suspention transplantation for vitiligo treatment

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200127046282N2

Enrollment

Registered

2021-05-28

Start date

2021-06-10

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. disorders of pigmentation

Interventions

Intervention group: The pigment-free area is first removed and then the processed cell suspension is transferred to the desired area and covered with a suitable dressing..

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Having no treatment within past 6 months, No pregnancy or breast-feeding, Have a diagnosis of vitiligo with depigmented patch more than 5 cm despite receiving at least 3 months active treatment, No infection at recipient site, No history of keloid and or koebner phenomenon, No history of active hepatitis the B, C, or AIDS, No active uncontrolled chronic systemic disease

Exclusion criteria

Exclusion criteria: Vitiligo patients with active or progressive disease within last 12 months.

Design outcomes

Primary

Measure	Time frame
Repigmentation rate. Timepoint: Before, 1, 3 and 6 months after treatment. Method of measurement: The amount of melanin in the treated areas compared to before treatment using a maxameter device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Tehran University of Medical Sciences

sonazarebio@gmail.com009822215558

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026